#USA #Duluth #Bridge to Life #Pediatric Liver Transplant #ILTS 2026

Establishing New Standards in Pediatric Liver Transplantation

In a major advancement for pediatric medicine, a pioneering global study has laid down the first international framework for pediatric liver transplantation (PLT). This initiative comes after years of discussion around the need for standardized outcomes in this critical area of healthcare, where variances across regions and healthcare systems have often hindered advancements in patient care.

Presented as a late-breaking clinical trial at the 2026 International Congress of the International Liver Transplant Society (ILTS) in Geneva, Switzerland, the study assesses various metrics, including morbidity, complications, graft survival, and outcomes of recipients from different transplantation populations worldwide. The necessity for such a framework has become glaringly evident, as there has been no globally accepted standard for assessing pediatric liver transplant outcomes, which has made it challenging to guide donor selection, risk stratification, and post-transplant quality assessment.

Led by Dr. Sapana Verma and mentored by Professor Andrea Schlegel of the Cleveland Clinic, the study involved a thorough analysis of primary pediatric liver transplantations performed between 2000 and 2024 across nine high-volume transplant centers in North America, Asia, Europe, South America, and the Africa/Middle East regions. Dr. Verma expressed the urgent need for such benchmarks, stating, "Globally accepted reference standards for pediatric liver transplantation have been sorely lacking. We aimed to establish international benchmarks for morbidity and survival post-liver transplantation and create a data-driven decision-making framework for donor selection within heterogeneous pediatric subgroups.”

The findings reveal notable outcomes, including a significantly lower incidence of severe morbidity, reduced renal, vascular, and biliary complications, as well as shorter hospitalization and intensive care durations. This benchmarking model brings awareness to the differences in outcomes among diverse pediatric populations, creating a scalable platform for comprehensive quality assessments and risk-adjusted outcome analyses.

Additionally, the research team is planning future endeavors to expand their study pool to over 10,000 recipients, which will help establish definitive global benchmarks, validating outcome thresholds based on crucial factors like age, weight, liver disease etiology, type of transplant, and combined risk profiles of the recipients.

Don Webber, President and CEO of Bridge to Life Ltd., highlighted the significance of standard benchmarks, stating, “Pediatric transplantation has never benefitted from normalized benchmarks that exist in adult transplantation. As the field advances towards precise graft assessments and optimized preservation strategies, solid benchmarks become paramount. These standards will not only define success but also aid in improving access to safe transplantation for more pediatric patients around the world.”

In conjunction with these findings, research involving Bridge to Life's hypothermic oxygenated perfusion (HOPE) system demonstrated HOPE's safety and efficacy within the pediatric liver transplantation context, reinforcing the growing trend of machine perfusion and viability-guided decision-making in this specialized population.

As pediatric transplantation continues to evolve towards more individualized donor selections and a broader application of advanced preservation technologies, these newly established benchmarks serve as a vital foundation for the next generation of clinical decisions. While benchmarking helps set attainable goals, advanced preservation strategies like HOPE promise to bridge the gap between high-risk grafts and benchmark outcomes, thus improving overall transplantation success rates.

About Bridge to Life Ltd

Bridge to Life Ltd is a global innovator in organ preservation technologies and solutions, offering leading products such as Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System. With a focus on quality, innovation, and accessibility, the company collaborates with top transplantation centers and organ procurement organizations worldwide.